‘We’re really happy with the team at Scius and their support for both rounds of our financing announcements. Highlighting engagement from both investors as well as funding from the EIC has been incredibly valuable to underscore our position as industry leaders in oncolytic viruses. We were delighted by the coverage achieved in the major trade publications.’

Akseli Hemminki, CEO of TILT Biotherapeutics